Tumor bearing decreases systemic acute inflammation in rats – role of mast cell degranulation

Abstract

Tumor bearing can limit mast cell function and vascular events in acute systemic inflammation in rats, without changes in neutrophil migration.

The involvement of the HO-1 pathway in the anti-inflammatory action of a sulfated polysaccharide isolated from the red seaweed Gracilaria birdiae

“…These results suggest that the anti-edematogenic response of SP-Gb is complex and may be related to the inhibition of both neutrophil migration and the release of vasoactive amines. This is probably a result of the anti-histaminic effect that may be caused by the inhibition of mast cell degranulation [35,36].…”

Participation of the NO/cGMP/K+ATP pathway in the antinociception induced by Walker tumor bearing in rats

“…We also observed that 15 days after tumor inoculation, animal mortality reached 100% (3). Thus, in this study, we evaluated the effects of tumor bearing on the 4th and 7th day after tumor inoculation.…”

“…Recently, our group demonstrated that Walker tumor bearing can limit mast cell function and vascular events in acute systemic inflammation models in rats, without changes in neutrophil migration (3). In the present study, our results demonstrate that Walker tumor bearing produced a peripheral antinociceptive effect in PGE 2 - or carrageenan-induced mechanical hypernociception, and this effect was mediated at least in part by activation of the NO/cGMP pathway, followed by the opening of KATP channels.…”

“…The Walker 256 tumor is widely utilized in experimental cancer research due to its easy transplantation, lack of regression or strain specificity, and rarity of spontaneous metastases (2). Recently, our group demonstrated that Walker 256 tumor implantation limits mast cell function and vascular events in acute inflammation in rats, without changes in neutrophil migration (3). …”

Ascorbic Acid (Vitamin C)-Mediated Protection on Mutagenic Potentials of Cisplatin in Mice Bearing Ascites Dalton ’s Lymphoma

“…Most of the studies involving implication of ascorbic acid in the modulation of antitumor effects or toxicities induced by various anticancer drugs have been done separately in cancer cell lines/tumors in vivo or in normal animals, respectively. Since cancers may alter the metabolic and endocrine equilibrium in the host (Barbosa et al, 2009), it is reasonable that the ascorbic acid-mediated protective strategies on cisplatin-induced mutagenic effects should be tested in tumor-bearing hosts which may also propose that inspective protective agents are useful in enhancing therapeutic efficacy. Our recent studies have shown that the combination treatment using ascorbic acid with cisplatin show better antitumor activity and reduced tissue toxicities in the hosts (Amenla et al, 2013;Longchar and Prasad, 2015).…”